| Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ... Nature medicine 21 (7), 795-801, 2015 | 708 | 2015 |
| Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ... Cancer discovery 3 (6), 658-673, 2013 | 519 | 2013 |
| Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of … A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ... The Lancet Oncology 17 (6), 738-746, 2016 | 496 | 2016 |
| Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1) A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Cancer discovery 7 (4), 400-409, 2017 | 410 | 2017 |
| NTRK gene fusions as novel targets of cancer therapy across multiple tumour types A Amatu, A Sartore-Bianchi, S Siena ESMO open 1 (2), e000023, 2016 | 265 | 2016 |
| Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, ... Science translational medicine 6 (224), 224ra26-224ra26, 2014 | 224 | 2014 |
| BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis C Cremolini, M Di Bartolomeo, A Amatu, C Antoniotti, R Moretto, ... Annals of oncology 26 (10), 2092-2097, 2015 | 146 | 2015 |
| Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer A Sartore-Bianchi, E Ardini, R Bosotti, A Amatu, E Valtorta, A Somaschini, ... JNCI: Journal of the National Cancer Institute 108 (1), 2016 | 101 | 2016 |
| Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer L Barault, A Amatu, G Siravegna, A Ponzetti, S Moran, A Cassingena, ... Gut 67 (11), 1995-2005, 2018 | 99 | 2018 |
| Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer A Amatu, A Sartore-Bianchi, C Moutinho, A Belotti, K Bencardino, ... Clinical cancer research 19 (8), 2265-2272, 2013 | 96 | 2013 |
| Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer L Barault, A Amatu, FE Bleeker, C Moutinho, C Falcomata, V Fiano, ... Annals of oncology 26 (9), 1994-1999, 2015 | 94 | 2015 |
| Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 … F Leone, D Marino, S Cereda, R Filippi, C Belli, R Spadi, G Nasti, ... Cancer 122 (4), 574-581, 2016 | 89 | 2016 |
| Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. S Siena, A Sartore-Bianchi, S Lonardi, L Trusolino, C Martino, ... Journal of Clinical Oncology 33 (15_suppl), 3508-3508, 2015 | 76 | 2015 |
| Adaptive mutability of colorectal cancers in response to targeted therapies M Russo, G Crisafulli, A Sogari, NM Reilly, S Arena, S Lamba, A Bartolini, ... Science 366 (6472), 1473-1480, 2019 | 72 | 2019 |
| OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma G Poggi, A Amatu, B Montagna, P Quaretti, C Minoia, C Sottani, L Villani, ... Cardiovascular and interventional radiology 32 (6), 1187-1192, 2009 | 71 | 2009 |
| Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy? A Amatu, K Bencardino, A Sartore-Bianchi, S Siena Annals of translational medicine 1 (2), 2013 | 66 | 2013 |
| Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors G Poggi, P Quaretti, C Minoia, G Bernardo, MR Bonora, R Gaggeri, ... Anticancer research 28 (6B), 3835-3842, 2008 | 62 | 2008 |
| Effect of KRAS and BRAF mutations on survival of metastatic colorectal cancer after liver resection: a systematic review and meta-analysis F Tosi, E Magni, A Amatu, G Mauri, K Bencardino, M Truini, S Veronese, ... Clinical colorectal cancer 16 (3), e153-e163, 2017 | 61 | 2017 |
| Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer A Amatu, A Somaschini, G Cerea, R Bosotti, E Valtorta, P Buonandi, ... British journal of cancer 113 (12), 1730-1734, 2015 | 57 | 2015 |
| Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1) Cancer … A Drilon, S Siena, SI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Published by S. Karger AG, Basel www. karger. com/cro Gupta et al.: A …, 2019 | 46 | 2019 |
Salvatore SienaUniversitą degli Studi di Milano, Niguarda Cancer Center, Grande Ospedale Metropolitano NiguardaEmail verificata su unimi.it
